Top Biotech Stocks To Watch Today – April 28th

SpringWorks Therapeutics, AbbVie, Thermo Fisher Scientific, Vertex Pharmaceuticals, and Danaher are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

Shares of SWTX stock traded up $1.43 during trading on Monday, hitting $46.15. The company’s stock had a trading volume of 65,478,113 shares, compared to its average volume of 1,730,151. The company has a market cap of $3.46 billion, a PE ratio of -13.26 and a beta of 0.79. The business has a fifty day moving average of $46.20 and a 200-day moving average of $40.64. SpringWorks Therapeutics has a 52 week low of $28.21 and a 52 week high of $62.00.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV stock traded up $4.33 during midday trading on Monday, hitting $190.39. The company’s stock had a trading volume of 3,870,997 shares, compared to its average volume of 6,037,570. AbbVie has a 1 year low of $153.58 and a 1 year high of $218.66. The stock has a market cap of $336.79 billion, a price-to-earnings ratio of 79.29, a PEG ratio of 1.62 and a beta of 0.55. The stock’s 50-day moving average price is $196.85 and its 200 day moving average price is $187.13. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

NYSE TMO traded down $4.07 during trading hours on Monday, reaching $420.18. 833,254 shares of the company were exchanged, compared to its average volume of 1,740,216. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $158.61 billion, a P/E ratio of 25.41, a P/E/G ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific has a 1 year low of $409.85 and a 1 year high of $627.88. The business’s 50 day simple moving average is $487.28 and its 200-day simple moving average is $526.70.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Vertex Pharmaceuticals stock traded down $0.41 during trading on Monday, hitting $493.43. The stock had a trading volume of 309,731 shares, compared to its average volume of 1,333,354. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $489.78 and its two-hundred day moving average is $466.28. Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The stock has a market cap of $126.71 billion, a price-to-earnings ratio of -223.64, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of DHR stock traded down $1.90 on Monday, hitting $195.25. 677,586 shares of the stock were exchanged, compared to its average volume of 3,344,631. The firm’s 50 day moving average is $200.87 and its two-hundred day moving average is $223.98. Danaher has a one year low of $171.00 and a one year high of $281.70. The firm has a market capitalization of $139.73 billion, a PE ratio of 36.93, a P/E/G ratio of 2.66 and a beta of 0.86. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.